The Only FDA-Cleared Endovascular Robot — And Wall Street Is Ignoring It

MBOT: The Launch Window Before the Breakout - With the world's only FDA-cleared single-use endovascular robot entering its full commercial launch at SIR in April 2026, Microbot Medical sits at a binary inflection — a micro-cap with institutional-grade clinical data, a growing hospital roster, and a community coiling tighter around a potential re-rating. The company's ACCESS-PVI pivotal trial data offers the kind of clinical headline that converts surgeons: 100% robotic navigation success and a 92% relative reduction in radiation exposure to the operating physician. In a specialty where interventionalists accumulate significant lifetime radiation burdens — and where musculoskeletal strain from heavy lead PPE is a career-limiting reality — LIBERTY does not merely offer incremental improvement. It offers a structural solution to an occupational health problem that the AMA has now formally elevated in its policy framework. - https://equity4keeps.com/MBOT_Market_Intelligence_Brief_1.html

Join this channel to get access to perks:
https://www.youtube.com/channel/UCUy6q6JP0G4FskWtF3yj0-g/join

Consider Supporting this Channel via PayPal: https://www.paypal.com/donate/?hosted_button_id=7G8U47SFTSWLL

MBOT: Buy Before April 2026 or Regret It Forever.
The SIR Conference Could Change Everything for MBOT — Here's What You Need to Know.
You Have Weeks Left to Buy MBOT Before the Full Market Launch.
MBOT's Full Market Release Is Coming — Are You Positioned?
The April 2026 Catalyst That Could Reprice MBOT Overnight.
Last Chance to Buy MBOT at $2.54? The Launch Window Is Closing.
MBOT: The 30-Day Window Before This Stock Moves.
Why Retail Traders Are Loading Up on MBOT Right Now.

Видео The Only FDA-Cleared Endovascular Robot — And Wall Street Is Ignoring It канала Equity4keeps